Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aronoff, S.
Right arrow Articles by Schneider, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aronoff, S.
Right arrow Articles by Schneider, R. L.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes Care, Vol 23, Issue 11 1605-1611, Copyright © 2000 by American Diabetes Association

ARTICLES

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group

S Aronoff, S Rosenblatt, S Braithwaite, JW Egan, AL Mathisen and RL Schneider
Research Institute of Dallas, Texas, USA.

OBJECTIVE: To evaluate the efficacy and safety of four doses of pioglitazone monotherapy in the treatment of patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: There were 408 patients randomized in this multicenter double-blind placebo-controlled clinical trial. Patients who had HbA1c > or = 7.0%, fasting plasma glucose (FPG) > or = 140 mg/dl, and C-peptide > 1 ng/ml were randomized to receive placebo or 7.5, 15, 30, or 45 mg pioglitazone administered once a day for 26 weeks. RESULTS: Patients treated with 15, 30, or 45 mg pioglitazone had significant mean decreases in HbA1c (range -1.00 to -1.60% difference from placebo) and FPG (-39.1 to -65.3 mg/dl difference from placebo). The decreases in FPG were observed as early as the second week of therapy; maximal decreases occurred after 10-14 weeks and were maintained until the end of therapy (week 26). In the 15-, 30-, or 45-mg pioglitazone groups, there were significant mean percent decreases in triglycerides, significant mean percent increases in HDL cholesterol, and only small percent changes in total cholesterol and LDL. The subset of patients naive to therapy had greater improvements in HbA1c and FPG (difference from placebo of -2.55% and -79.9 mg/dl for the 45-mg group) compared with previously treated patients. The overall adverse event profile of pioglitazone was similar to that of placebo. There was no evidence of drug-induced hepatotoxicity or drug-induced elevations of alanine aminotransferase levels in this study CONCLUSIONS: Pioglitazone monotherapy significantly improves HbA1c and FPG while producing beneficial effects on serum lipids in patients with type 2 diabetes with no evidence of drug-induced hepatotoxicity.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
E. Selvin, S. Bolen, H.-C. Yeh, C. Wiley, L. M. Wilson, S. S. Marinopoulos, L. Feldman, J. Vassy, R. Wilson, E. B. Bass, et al.
Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review
Arch Intern Med, October 27, 2008; 168(19): 2070 - 2080.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
X. Ruan, F. Zheng, and Y. Guan
PPARs and the kidney in metabolic syndrome
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1032 - F1047.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
D. F. Kruger
Exploring the Pharmacotherapeutic Options for Treating Type 2 Diabetes
The Diabetes Educator, May 1, 2008; 34(Supplement_3): 60S - 65S.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. K. McGuire and S. E. Inzucchi
New Drugs for the Treatment of Diabetes Mellitus: Part I: Thiazolidinediones and Their Evolving Cardiovascular Implications
Circulation, January 22, 2008; 117(3): 440 - 449.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Hou, R. Liu, S. Ross, E. J. Smart, H. Zhu, and W. Gong
Crystallographic Studies of Human MitoNEET
J. Biol. Chem., November 16, 2007; 282(46): 33242 - 33246.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
P. Hollander
Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Diabetes Spectr, July 1, 2007; 20(3): 159 - 165.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C. Menzaghi, V. Trischitta, and A. Doria
Genetic Influences of Adiponectin on Insulin Resistance, Type 2 Diabetes, and Cardiovascular Disease
Diabetes, May 1, 2007; 56(5): 1198 - 1209.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
A. H Barnett
Summarising the use of thiazolidinediones with insulin
The British Journal of Diabetes & Vascular Disease, March 1, 2007; 7(2): 75 - 80.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. J. Serlie, G. Allick, J. E. Groener, M. T. Ackermans, R. Heijligenberg, B. C. Voermans, J. M. Aerts, A. J. Meijer, and H. P. Sauerwein
Chronic Treatment with Pioglitazone Does Not Protect Obese Patients with Diabetes Mellitus Type II from Free Fatty Acid-Induced Insulin Resistance
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 166 - 171.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
W. S. Shim, S. K. Kim, H. J. Kim, E. S. Kang, C. W. Ahn, S. K. Lim, H. C. Lee, and B. S. Cha
Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes.
Eur. J. Endocrinol., October 1, 2006; 155(4): 615 - 622.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
P. F. Pilch and N. Bergenhem
Pharmacological Targeting of Adipocytes/Fat Metabolism for Treatment of Obesity and Diabetes
Mol. Pharmacol., September 1, 2006; 70(3): 779 - 785.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
H. N. Hodis, W. J. Mack, L. Zheng, Y. Li, M. Torres, D. Sevilla, Y. Stewart, B. Hollen, K. Garcia, P. Alaupovic, et al.
Effect of Peroxisome Proliferator-Activated Receptor {gamma} Agonist Treatment on Subclinical Atherosclerosis in Patients With Insulin-Requiring Type 2 Diabetes
Diabetes Care, July 1, 2006; 29(7): 1545 - 1553.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Kendall, C. J. Rubin, P. Mohideen, J.-M. Ledeine, R. Belder, J. Gross, P. Norwood, M. O'Mahony, K. Sall, G. Sloan, et al.
Improvement of Glycemic Control, Triglycerides, and HDL Cholesterol Levels With Muraglitazar, a Dual ({alpha}/{gamma}) Peroxisome Proliferator-Activated Receptor Activator, in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: A double-blind, randomized, pioglitazone-comparative study
Diabetes Care, May 1, 2006; 29(5): 1016 - 1023.
[Abstract] [Full Text] [PDF]

Home page
 DOC NewsHome page
E. T. Beckley
Diabetes Drug Reportedly Cuts Death, Heart Attack, Stroke Risk
DOC News, December 1, 2005; 2(12): 1 - 11.
[Full Text]

Home page
 DiabetesHome page
J. K. Wolford, K. A. Yeatts, S. K. Dhanjal, M. H. Black, A. H. Xiang, T. A. Buchanan, and R. M. Watanabe
Sequence Variation in PPARG May Underlie Differential Response to Troglitazone
Diabetes, November 1, 2005; 54(11): 3319 - 3325.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. Kahn, J. Buse, E. Ferrannini, and M. Stern
The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, September 1, 2005; 28(9): 2289 - 2304.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
I. W Campbell
Pioglitazone -- an oral antidiabetic agent and metabolic syndrome modulator. Can theory translate into practice?
The British Journal of Diabetes & Vascular Disease, July 1, 2005; 5(4): 209 - 216.
[Abstract] [PDF]

Home page
 Diabetes CareHome page
R. B. Goldberg, D. M. Kendall, M. A. Deeg, J. B. Buse, A. J. Zagar, J. A. Pinaire, M. H. Tan, M. A. Khan, A. T. Perez, S. J. Jacober, et al.
A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
Diabetes Care, July 1, 2005; 28(7): 1547 - 1554.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
A. Reifel-Miller, K. Otto, E. Hawkins, R. Barr, W. R. Bensch, C. Bull, S. Dana, K. Klausing, J.-A. Martin, R. Rafaeloff-Phail, et al.
A Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Dual Agonist with a Unique in Vitro Profile and Potent Glucose and Lipid Effects in Rodent Models of Type 2 Diabetes and Dyslipidemia
Mol. Endocrinol., June 1, 2005; 19(6): 1593 - 1605.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
B. Kimmel and S. E. Inzucchi
Oral Agents for Type 2 Diabetes: An Update
Clin. Diabetes, April 1, 2005; 23(2): 64 - 76.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. H. Xiang, R. K. Peters, S. L. Kjos, C. Ochoa, A. Marroquin, J. Goico, S. Tan, C. Wang, S. P. Azen, C.-r. Liu, et al.
Effect of Thiazolidinedione Treatment on Progression of Subclinical Atherosclerosis in Premenopausal Women at High Risk for Type 2 Diabetes
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1986 - 1991.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
F. A. Masoudi, S. E. Inzucchi, Y. Wang, E. P. Havranek, J. M. Foody, and H. M. Krumholz
Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study
Circulation, February 8, 2005; 111(5): 583 - 590.
[Abstract] [Full Text] [PDF]

Home page
 CMAJHome page
A. Y.Y. Cheng and I. G. Fantus
Oral antihyperglycemic therapy for type 2 diabetes mellitus
Can. Med. Assoc. J., January 18, 2005; 172(2): 213 - 226.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
T. Bongartz, B. Coras, T. Vogt, J. Scholmerich, and U. Muller-Ladner
Treatment of active psoriatic arthritis with the PPAR{gamma} ligand pioglitazone: an open-label pilot study
Rheumatology, January 1, 2005; 44(1): 126 - 129.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Schernthaner, D. R. Matthews, B. Charbonnel, M. Hanefeld, P. Brunetti, and on Behalf of the Quarter Study Group
Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial
J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6068 - 6076.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y. Guan
Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome
J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2801 - 2815.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. Chiquette, G. Ramirez, and R. DeFronzo
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Arch Intern Med, October 25, 2004; 164(19): 2097 - 2104.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
H. Yki-Jarvinen
Thiazolidinediones
N. Engl. J. Med., September 9, 2004; 351(11): 1106 - 1118.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
G. Boden and M. Laakso
Lipids and Glucose in Type 2 Diabetes: What is the cause and effect?
Diabetes Care, September 1, 2004; 27(9): 2253 - 2259.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Zander, A. Christiansen, S. Madsbad, and J. Juul Holst
Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes
Diabetes Care, August 1, 2004; 27(8): 1910 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. Charbonnel, J. Dormandy, E. Erdmann, M. Massi-Benedetti, and A. Skene
The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5,238 patients
Diabetes Care, July 1, 2004; 27(7): 1647 - 1653.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. H. Tan, D. Johns, and N. B. Glazer
Pioglitazone Reduces Atherogenic Index of Plasma in Patients with Type 2 Diabetes
Clin. Chem., July 1, 2004; 50(7): 1184 - 1188.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
C M. B Edwards
GLP-1: target for a new class of antidiabetic agents?
J R Soc Med, June 1, 2004; 97(6): 270 - 274.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. F. Saad, S. Greco, K. Osei, A. J. Lewin, C. Edwards, M. Nunez, and R. R. Reinhardt
Ragaglitazar Improves Glycemic Control and Lipid Profile in Type 2 Diabetic Subjects: A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm
Diabetes Care, June 1, 2004; 27(6): 1324 - 1329.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. M. Krauss
Lipids and Lipoproteins in Patients With Type 2 Diabetes
Diabetes Care, June 1, 2004; 27(6): 1496 - 1504.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Gehrmann, M. Brunner, K. Pfister, A. Reichle, E. Kremmer, and G. Multhoff
Differential Up-Regulation of Cytosolic and Membrane-Bound Heat Shock Protein 70 in Tumor Cells by Anti-Inflammatory Drugs
Clin. Cancer Res., May 15, 2004; 10(10): 3354 - 3364.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
Q. Guo, S. P. Sahoo, P.-R. Wang, D. P. Milot, M. C. Ippolito, M. S. Wu, J. Baffic, C. Biswas, M. Hernandez, M.-H. Lam, et al.
A Novel Peroxisome Proliferator-Activated Receptor {alpha}/{gamma} Dual Agonist Demonstrates Favorable Effects on Lipid Homeostasis
Endocrinology, April 1, 2004; 145(4): 1640 - 1648.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. Ludvik, B. Neuffer, and G. Pacini
Efficacy of Ipomoea batatas (Caiapo) on Diabetes Control in Type 2 Diabetic Subjects Treated With Diet
Diabetes Care, February 1, 2004; 27(2): 436 - 440.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. M. Lawrence, J. Reid, G. J. Taylor, C. Stirling, and J. P.D. Reckless
Favorable Effects of Pioglitazone and Metformin Compared With Gliclazide on Lipoprotein Subfractions in Overweight Patients With Early Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(1): 41 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Hanefeld, P. Brunetti, G. H. Schernthaner, D. R. Matthews, and B. H. Charbonnel
One-Year Glycemic Control With a Sulfonylurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients With Type 2 Diabetes
Diabetes Care, January 1, 2004; 27(1): 141 - 147.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
A. R. Diani, G. Sawada, B. Wyse, F. T. Murray, and M. Khan
Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes
Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E116 - E122.
[Abstract] [Full Text]

Home page
 Diabetes CareHome page
M. B. Davidson
Is Treatment of Insulin Resistance Beneficial Independent of Glycemia?
Diabetes Care, November 1, 2003; 26(11): 3184 - 3186.
[Full Text] [PDF]

Home page
 J Clin PharmacolHome page
B. K. Skrumsager, K. K. Nielsen, M. Muller, G. Pabst, P. G. Drake, and B. Edsberg
Ragaglitazar: The Pharmacokinetics, Pharmacodynamics, and Tolerability of a Novel Dual PPAR{alpha} and {gamma} Agonist in Healthy Subjects and Patients with Type 2 Diabetes
J. Clin. Pharmacol., November 1, 2003; 43(11): 1244 - 1256.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
V. De Leo, A. la Marca, and F. Petraglia
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
Endocr. Rev., October 1, 2003; 24(5): 633 - 667.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
J. P.H. van Wijk, E. J.P. de Koning, E. P. Martens, and T. J. Rabelink
Thiazolidinediones and Blood Lipids in Type 2 Diabetes
Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1744 - 1749.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Winkler, T. Konrad, S. Fullert, I. Friedrich, R. Destani, M. W. Baumstark, K. Krebs, H. Wieland, and W. Marz
Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension: A double-blind, placebo-controlled study
Diabetes Care, September 1, 2003; 26(9): 2588 - 2594.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
Y. Miyazaki, H. He, L. J. Mandarino, and R. A. DeFronzo
Rosiglitazone Improves Downstream Insulin Receptor Signaling in Type 2 Diabetic Patients
Diabetes, August 1, 2003; 52(8): 1943 - 1950.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
W. N. Kernan, S. E. Inzucchi, C. M. Viscoli, L. M. Brass, D. M. Bravata, G. I. Shulman, J. C. McVeety, and R. I. Horwitz
Pioglitazone Improves Insulin Sensitivity Among Nondiabetic Patients With a Recent Transient Ischemic Attack or Ischemic Stroke
Stroke, June 1, 2003; 34(6): 1431 - 1436.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. K. S. Leow, C. L. Addy, and C. S. Mantzoros
Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies
J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1961 - 1976.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
I. Pavo, G. Jermendy, T. T. Varkonyi, Z. Kerenyi, A. Gyimesi, S. Shoustov, M. Shestakova, M. Herz, D. Johns, B. J. Schluchter, et al.
Effect of Pioglitazone Compared with Metformin on Glycemic Control and Indicators of Insulin Sensitivity in Recently Diagnosed Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1637 - 1645.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
C. L. Brand, J. Sturis, C. F. Gotfredsen, J. Fleckner, C. Fledelius, B. F. Hansen, B. Andersen, J.-M. Ye, P. Sauerberg, and K. Wassermann
Dual PPARalpha /gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats
Am J Physiol Endocrinol Metab, April 1, 2003; 284(4): E841 - E854.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Bluher, G. Lubben, and R. Paschke
Analysis of the Relationship Between the Pro12Ala Variant in the PPAR-{gamma}2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 Diabetes
Diabetes Care, March 1, 2003; 26(3): 825 - 831.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
R. K. Campbell and J. White
Counseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient Setting
The Diabetes Educator, November 1, 2002; 28(6): 938 - 957.
[PDF]

Home page
 JAMAHome page
J. A. Beckman, M. A. Creager, and P. Libby
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
JAMA, May 15, 2002; 287(19): 2570 - 2581.
[Abstract] [Full Text] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
K. Winkler, I. Friedrich, M. W Baumstark, H. Wieland, and W. Marz
Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus
The British Journal of Diabetes & Vascular Disease, March 1, 2002; 2(2): 143 - 148.
[Abstract] [PDF]

Home page
 Diabetes CareHome page